Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Akari Therapeutics presented at the Virtual Investor "Why Now" conference to showcase its novel antibody drug conjugates (ADCs) with PH1 RNA splicing modulator payloads targeting cancer. The company emphasizes the potential advantages of its lead candidate AKTX-101 and plans to initiate a First-In-Human trial by mid-2027, aiming to address limitati…